Elin Rowen
Impact in
-
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
-
- Nanoparticle-Based Drug Delivery
Papers in
- Oncology 8
- Lung Cancer Research Studies 3
- Cancer Treatment and Pharmacology 3
- Cancer Immunotherapy and Biomarkers 3
- Colorectal Cancer Treatments and Studies 3
-
- Lung Cancer Treatments and Mutations 4
- Brain Metastases and Treatment 2
- Renal cell carcinoma treatment 1
- Co-authors
- Nikolai A. Podoltsev (2 shared papers)Muhammad Wasif Saif (2 shared papers)José A. Figueroa (1 shared paper)Mark S. Rubin (1 shared paper)Robert O. Kerr (1 shared paper)Lucia B. Jilaveanu (2 shared papers)Anne C. Chiang (4 shared papers)Sarah B. Goldberg (4 shared papers)
- Journals
- Journal of Clinical Oncology (8 papers)Cancer Investigation (2 papers)Molecular Cancer Therapeutics (1 paper)Journal of Thoracic Oncology (1 paper)
- Partner nations
- United States
In The Last Decade
Elin Rowen
11 papers receiving 143 citations
Peers
Comparison fields: 5 of 30
- Oncology 78
- Biomaterials 40
- Pulmonary and Respiratory Medicine 52
- Genetics 11
- Pharmaceutical Science 6
Countries citing papers authored by Elin Rowen
This map shows the geographic impact of Elin Rowen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elin Rowen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elin Rowen more than expected).
Fields of papers citing papers by Elin Rowen
This network shows the impact of papers produced by Elin Rowen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elin Rowen. The network helps show where Elin Rowen may publish in the future.
Co-authors
The 25 scholars most cited alongside Elin Rowen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 65 | |
| 2 | 2015 | 29 | |
| 3 | 2018 | 28 | |
| 4 | 2009 | 8 | |
| 5 | 2010 | 4 | |
| 6 | 2011 | 2 | |
| 7 | 2023 | 2 | |
| 8 | A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors. | 2007 | 2 |
| 9 | 2023 | 1 | |
| 10 | 2009 | 1 | |
| 11 | 2005 | 1 | |
| 12 | 2010 | 0 |
About Elin Rowen
Elin Rowen is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research and Molecular Biology, having authored 12 papers that have together received 143 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Research Studies (3 papers), Cancer Treatment and Pharmacology (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Brain Metastases and Treatment (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Renal cell carcinoma treatment (1 paper). The work is most often cited by research in Oncology (78 citations), Biomaterials (40 citations), Pulmonary and Respiratory Medicine (52 citations), Genetics (11 citations) and Pharmaceutical Science (6 citations). Elin Rowen has collaborated with scholars based in United States. Frequent co-authors include Nikolai A. Podoltsev, Muhammad Wasif Saif, José A. Figueroa, Mark S. Rubin, Robert O. Kerr, Lucia B. Jilaveanu, Anne C. Chiang, Sarah B. Goldberg, Heather Gerrish and Amit Mahajan. Their work appears in journals such as Journal of Clinical Oncology, Cancer Investigation, Molecular Cancer Therapeutics and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.